Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IASO-782 in Autoimmune Hematological Diseases
NCT06534021Phase 1Recruiting
- Sponsor
- Reindeer Biotech
- Start
- Aug 2024
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IASO-782 in immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA) (2 arms), sponsored by Reindeer Biotech. Primary endpoint: Adverse Events at 12 weeks. Started Aug 2024; status: recruiting.
02
Drugs
IASO-782
03
Conditions
immune thrombocytopenia (ITP)warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on NCT06534021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06534021.